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Purpose: To determine the safety and efficacy of the application of transcutaneous 
(transpalpebral) microcurrent stimulation to slow progression of dry and wet macular degenera-
tion or improve vision in dry and wet macular degeneration.
Methods: Seventeen patients aged between 67 and 95 years with an average age of 83 years 
were selected to participate in the study over a period of 3 months in two eye care centers. 
There were 25 eyes with dry age-related macular degeneration (DAMD) and six eyes with wet 
age-related macular degeneration (WAMD). Frequency-specific microcurrent stimulation was 
applied in a transpalpebral manner, using two programmable dual channel microcurrent units 
delivering pulsed microcurrent at 150 µA for 35 minutes once a week. The frequency pairs 
selected were based on targeting tissues, which are typically affected by the disease combined 
with frequencies that target disease processes. Early Treatment Diabetic Retinopathy Study or 
Snellen visual acuity (VA) was measured before and after each treatment session. All treatment 
was administered in a clinical setting.
Results: Significant increases were seen in VA in DAMD (P=0.012, Wilcoxon one-sample 
test), but in WAMD, improvements did not reach statistical significance (P=0.059). In DAMD 
eyes, twice as many patients showed increase in VA (52%) compared to those showing dete-
rioration (26%), with improvements being often sizeable, whereas deteriorations were usually 
very slight. In WAMD eyes, five of six (83%) patients showed an increase and none showed 
deterioration.
Conclusion: The substantial changes observed over this period, combined with continued 
improvement for patients who continued treatment once a month, are encouraging for future 
studies. The changes observed indicate the potential efficacy of microcurrent to delay degenera-
tion and possibly improve age-related macular degeneration, both wet and dry. However, this 
study has no control arm, so results should be treated with caution. Randomized double-blind 
controlled studies are needed to determine long-term effects.
Keywords: microcurrent, macular degeneration, transpalpebral, transcutaneous, retinal 
disease
Introduction
Low-intensity micro-amperage current has been applied to retinal conditions for several 
decades under various circumstances. Henry Dor, MD, an ophthalmologist in Germany, 
used electrical currents to help individuals with amblyopia, retinochoroiditis, glau-
coma, and optic atrophy in 1873.1 In a summary paper by Gekeler and Bartz-Schmidt, 
subthreshold visual stimulation in inactive retinal implants leading to improvements in 
residual areas of vision was stated to be the result of a release of neurotrophic factors.2 
Twenty peer-reviewed publications in PubMed over the last 5 years reflect renewed 
interest in microcurrent therapy.3 Since then, transcorneal electrical stimulation (TES) 
and transpalpebral electrical stimulation (TPES)  placement of the electrodes over the 
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closed lid has been used. A study by Shinoda et al in 2008 
applied this approach to 16 patients with wet age-related 
macular degeneration (WAMD) and to five with dry age-
related macular degeneration (DAMD). They used four 
frequencies of 290 Hz, 31 Hz, 8.9 Hz, and 28 Hz delivered 
via a monophasic pulse at 800 µA. Subjects with both 
WAMD and DAMD showed statistically significant log of 
the minimum angle of resolution (logMAR) improvements, 
from 29.5 logMAR units to 31.8 logMAR units (WAMD, 
P=0.04) and from 39.8  logMAR units to 42.9 logMAR 
units (DAMD, P=0.04), comparing pre- and 4-week post-
treatment results.3 In 2013, Anastassiou published results 
from a randomized placebo-controlled exploratory trial 
with 22 patients using a TPES approach with variable fre-
quencies of 5–80 Hz at 150–220 µA twice a day treatment 
to eight spots around the eyes for 40 seconds per spot for 
1 week. At the end of the week, they found that seven out 
of 12 patients had an improvement in visual acuity (VA) 
of more than five letters (P=0.001). Similarly contrast 
sensitivity improved with an increase of .4.4 optotypes 
(P=0.006). Placebo controls had no statistically significant 
change in VA.4
Basic research both in vitro and in vivo demonstrat-
ing the safety and neuroprotective effects of electrical 
current stimulation has been done in a number of areas. 
Motor axonal regeneration, sensory nerve regeneration, 
and growth-associated gene expression were found to be 
significantly enhanced by brief periods of micro-amperage 
stimulation.5 Increased survival of retinal ganglion cells in 
rats following crushed optic nerve as well as significant delay 
of posttraumatic cell death was described.6,7 Increased visual 
evoked potential amplitude following optic nerve crush 
(early stage).5 Electroretinogram measurements showed 
amelioration of progressive photoreceptor degeneration 
following light-induced retinal damage,8 as well as neu-
roprotection through proinflammatory effects.9 Alteration 
in gene expression was demonstrated, where close to 500 
transcriptome changes were measured and included poten-
tially neuroprotective genes as well as genes that moderate 
the expression of tumor necrosis factor (TNF).10 Retinal 
photoreceptor protective effects were demonstrated in rho-
dopsin P347L-deficient rabbits via electroretinogram,11 as 
well as neuroprotection from ischemic damage.12 Increase 
in cerebral blood flow in rats following TES of trigeminal 
afferents even after being subjected to subarachnoid hemor-
rhage induced vasospasm.13 In all human studies, there were 
no adverse effects aside from short-term corneal irritation 
from the contact electrode and, in most cases, there were 
notable and sometimes significant improvements in vision. 
All studies were small; some had sham controls. Effective 
use of TES for eye conditions included nonarteritic ischemic 
neuropathy,14 branch retinal vein occlusion,15 Stargardt’s 
disease,16 retinitis pigmentosa,17 and Best vitelliform retin-
opathy.18 Frequency-specific microcurrent (FSM) has been 
used extensively in the field of physical medicine and reha-
bilitation for pain relief and accelerating tissue recovery.19 
This approach proposes that it is not only the microcurrents 
that have a positive effect on biological tissue but also the 
frequencies themselves. Frequencies are delivered via a 
square-wave pulse train. Square-wave pulse trains contain 
a wide range of harmonics, which can stimulate a resonance 
effect in target tissues. One well-known resonance effect is 
in sound acoustics breaking down the binding of lead atoms 
in crystal glass enabling it to shatter. In tissue pathology, 
the resonance could potentially break molecular bonds 
responsible for inflammation. For example, an animal model 
was used to test the anti-inflammatory effect in the immune 
system.20 Arachidonic acid was painted on mouse ears to 
create inflammation. The frequency combination of 40 Hz 
and 116 Hz for inflammation in the immune system was 
run through the ears immediately afterward, and ear thick-
ness measurements were made after treatment. In the sham 
treatment, a different frequency combination of 40 Hz/0 Hz 
was run, and the results were measured. The treatment group 
showed a 62% reduction of lipoxygenase-mediated inflam-
mation and 30% reduction of cyclooxygenase-mediated 
inflammation at 4 minutes, while the sham group showed 
no change. Treated ear thickness reduced by 62% compared 
to controls.20 All information about which frequencies are 
used with which tissues is derived from course information 
provided by www.frequencyspecific.com.
A human case study published in 2010 showed suc-
cessful treatment of herpes zoster on ophthalmic branch 
of CN V with FSM using 190-minute treatment at 230 Hz 
and 430 Hz.21 In a clinical study of pain, in 77 fibromyalgia 
patients, statistically significant subjective improvements 
in pain were associated with reductions in inflammatory 
cytokines by a factor of 10–20 times in 90 minutes: inter-
leukin (IL)-1 from 392 pg/mL to 21 pg/mL, TNF-α from 
299 pg/mL to 21 pg/mL, and IL-6 from 204 pg/mL to 
15 pg/mL.22 This study explored the question whether FSM 
utilizing a TPES approach could provide similar efficacy 
and safety results. Study objectives included change in VA 
from baseline to 3 months, changes in retinal thickness as 
measured by optical coherence tomography (OCT), and 
changes in microperimetry, as measured by Nidek MP-3 
microperimeter. Not all subjects were able to complete the 
microperimetry testing.
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Methods
Seventeen patients aged between 67 and 95 years with an aver-
age age of 82.9 years were tested and treated in two eye care 
centers located at the Retina Institute of Hawaii in Honolulu 
and a private practice in Castro Valley, CA, USA. There were 
25 eyes with DAMD and six eyes with WAMD. All patients 
were screened for inclusion after providing written informed 
consent. The research followed the tenants of the Declaration 
of Helsinki, and an independent review board application was 
completed and approved by Sterling Independent Review 
Board (Atlanta, GA, USA) prior to subject selection. The trial 
was registered with number NCT01790958.
Inclusion criterion were .50 years of age or older, 
male and female, history of retinal disease involvement, no 
antivascular endothelial growth factor treatments for at least 
3 months prior to the study, and no new antioxidant/vitamin 
supplementation for at least 6 months prior to the study. 
Subjects with WAMD were placed in the study only after 
they were medically cleared as having no active bleeding. 
Exclusion criteria included a history of noncompliance with 
regular medical visits, significant media opacities that might 
interfere with assessing VA, presence of pigment epithelial 
tears or rips, diabetic retinopathy, any known serious allergies 
to fluorescein dye, presence of retinal neovascularization, or 
any treatment with investigation agents in the past 30 days.
Screening procedures included best-corrected VA (VA 
determined by staff low vision optometrist), ophthalmic 
examination, intraocular pressure measurement, fluorescein 
angiography, fundus photography, and OCT per standard of 
care; these tests were performed no earlier than 14 days prior 
to initiation of the treatment and were performed by qualified 
personnel. Qualified personnel consisted of licensed low vision 
optometrists, ophthalmic technicians, and ophthalmologists.
After initial screening, patients returned for regular clinic 
examinations and diagnostic testing per standard of care. 
These visits were conducted depending on the type and 
severity of the retinal disease condition per standard of care. 
Vitals (blood pressure, weight, and pulse), VA, intraocular 
pressure measurements, OCT, and dilated eye examinations 
were performed per standard of care. Fundus photos, fluores-
cein angiograms, and microperimetry were obtained based 
on standard of care and severity of disease.
In some cases, VA was measured using Snellen acuity, 
which then was converted to the logMAR scores. In the cases 
of count fingers, hand motion, light perception, or no light per-
ception, the following convention was used: count fingers =1.6, 
hand motion =2.0, light perception =2.5, and no light percep-
tion =3.0 logMAR units, as described by Cohen et al.23 Because 
treatment intervals varied slightly from patient to patient, and 
patients were followed-up for varying lengths of time, in order 
to calculate mean logMAR changes over time it was necessary 
both to interpolate logMAR values between one time point and 
the next, and to make assumptions about the pattern of logMAR 
results beyond the longest follow-up time for each patient. It 
was therefore assumed that changes from one time point to the 
next followed a linear pattern. In this way, it was possible to 
derive an imputed logMAR score for every day from the start 
of treatment for each patient. The so-called linear increment 
method was then used to extrapolate beyond the follow-up of an 
individual patient.24 This method involves projecting the pattern 
of change for the individual patient beyond their own follow-up 
by allowing each individual’s values to follow the overall pattern 
of the whole cohort from day-to-day.24 Thus, the mean values 
are not compromised by dropouts. The standard error (SE) of the 
mean and, therefore, the confidence interval (CI) on the mean 
are based on the number of actual values at that time point; the 
values carried forward are used in calculating the mean, but not 
the SE. This method is used in Figures 3 and 4.
To evaluate the significance of overall changes in VA 
over time, the overall difference in the letter count was 
calculated for each patient and the significance of these dif-
ferences was evaluated using the Wilcoxon one-sample test 
(Wilcoxon signed-rank sum test); if differences were random, 
the median of these values was expected to be 0.
FSM stimulation was applied in a transpalpebral man-
ner, with flat carbon electrodes placed into chamois-type 
fabric, which was moistened with water and placed over 
the closed eyes; another electrode was placed at the base of 
the skull (Figure 1). Two small dual channel programmable 
Figure 1 Patient receiving microcurrent treatment.
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is  significant change in VA scores in DAMD (P=0.012, 
 Wilcoxon one-sample test). In WAMD, changes did not 
reach statistical significance (P=0.059). With only six values, 
all six WAMD eyes would have had to show improvements 
for this result to be significant, whereas, in fact, five eyes 
showed improvement and one showed no change. In DAMD 
eyes, twice as many patients showed a positive trend (52%) 
compared to those showing deterioration (26%), and the 
changes were often sizeable, whereas deteriorations were 
usually very slight (Figures 1 and 5). In WAMD eyes, five 
of six (83%) patients again showed a positive trend, while 
none showed deterioration.
Table 1 Va results for dry aMD
Eye no Pretreatment VA Posttreatment VA
1 20/40 20/20-
2 20/50 20/25-2
3 20/200 20/200
4 hM 1′ hM 1′
5 20/800+ 20/640-
6 20/320+ 20/160+
7 20/125+ 20/63-
8 20/25- 20/30+
9 20/80 20/80-
10 20/200- 20/80-
11 20/20 20/20+
12 20/40- 20/32+
13 20/100- 20/70+
14 CF at 4′ CF at 4′
15 20/50- 20/50
16 20/200 20/200
17 20/60 20/50
18 20/100 20/30-
19 20/250+ 20/50-
20 20/80+ 20/60-
21 20/125- 20/125–
22 20/60- 20/50-
23 20/400 20/160
24 20/800 20/800
25 20/1,000 20/1,000+
Abbreviations: AMD, age-related macular degeneration; CF, count fingers; 
hM, hand motion; Va, visual acuity.
microcurrent units utilizing a direct current source (Custom 
Care Manufacturing Microcurrent Technologies, Seattle, 
WA, USA, and Precision Distributing, Vancouver, WA, 
USA) were programmed with the FSM protocol. The treat-
ment time was 35 minutes, and all treatments were admin-
istered in a clinical setting. The frequency pairs selected 
were based on targeting tissues, which are typically affected 
by the disease and combining with frequencies that target 
disease processes. For example frequencies pairs included 
40 Hz with 95 Hz for inflammation in the retina and macula 
(137 Hz), scarring and inflammation in the arteries, veins, 
capillaries, and retina (3 Hz and 13 Hz with 62 Hz, 79 Hz, 
162 Hz, and 95 Hz) among others. Current was delivered at 
150 µA, and frequency was delivered via a ramped square-
wave pulse train. Early Treatment Diabetic Retinopathy 
Study or Snellen VA was measured before and after each 
treatment session, and subjective responses were recorded. 
Number of treatments was determined by condition severity 
and patient response. The number of treatments ranged from 
2 to 10, with an average of 4.8 sessions.
Results
Tables 1 and 2 show the VA scores before and after treatment. 
Absolute logMAR changes from the baseline values over 
the first 3 months are shown for DAMD and WAMD eyes 
in Figures 2 and 3, respectively. The no-change line is added 
for reference. Many eyes show an initial sharp logMAR 
drop, with a few patients showing no improvement or a very 
slight deterioration. Overall mean changes over time with 
95% CI on these means are shown for dry and wet eyes in 
Figures 4 and 5, respectively, using the approach described 
in the “Methods” section. For these mean changes, similar 
patterns are observed in both eyes, with a sharp fall, indicat-
ing improvement in VA, seen over approximately the first 
week or so, and continuing improvement throughout the first 
month. Subsequently, the logMAR scores appear to level off. 
There may be some slight deterioration in the next 2 months; 
though numbers become small, the CIs are wide. The upper 
95% CIs on these means are consistently well below 0, indi-
cating a highly statistically significant effect, which begins 
almost immediately. Choosing to compare logMAR values 
at 21 days, since only two WAMD eyes have follow-up 
at 30 days, whereas all six have follow-up at 21 days, the 
21-day logMAR mean was 3.8 SEs below 0 in DAMD eyes 
(P=0.0001) and 3.9 SEs below 0 in WAMD eyes (P=0.0001), 
a very similar order of magnitude of effect.
The histograms in Figures 6 and 7 show the mean 
letter changes from baseline to final visit by eye. There 
Table 2 Va results for wet aMD
Eye no Pretreatment VA Posttreatment VA
1 20/160-1 20/100+1
2 20/200 20/80-
3 20/60- 20/60+
4 20/70 20/50-
5 20/1,000+ 20/800
6 20/100- 20/80-
Abbreviations: aMD, age-related macular degeneration; Va, visual acuity.
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Figure 2 Dry aMD eyes: absolute logMar differences from starting values for each 
patient, plotted over first 3 months only.
Notes: each color represents a different eye. There is an additional dotted axis 
line drawn at 0.
Abbreviations: aMD, age-related macular degeneration; logMar, log of the 
minimum angle of resolution.
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Figure 3 Wet aMD eyes: absolute logMar differences from starting values for each 
patient, plotted over first 3 months only.
Notes: each color represents a different eye. There is an additional dotted axis 
line drawn at 0.
Abbreviations: aMD, age-related macular degeneration; logMar, log of the 
minimum angle of resolution.
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Figure 4 Dry aMD eyes: mean absolute logMar differences from starting values 
with 95% confidence intervals on these means.
Notes: Dotted lines represent the 95% confidence limits on the mean.
Abbreviations: aMD, age-related macular degeneration; logMar, log of the 
minimum angle of resolution.
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Figure 5 Wet aMD eyes: mean absolute logMar differences from starting values 
with 95% confidence intervals on these means.
Notes: Dotted lines represent the 95% confidence limits on the mean.
Abbreviations: aMD, age-related macular degeneration; logMar, log of the 
minimum angle of resolution.
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Figure 6 Dry aMD eyes: total letter change.
Notes: Blue = improvement, red = deterioration, and green = no change.
Abbreviation: aMD, age-related macular degeneration.
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Figure 7 Wet aMD eyes: total letter change.
Notes: Blue = improvement, red = deterioration (no eyes deteriorated in this 
instance), and green = no change.
Abbreviation: aMD, age-related macular degeneration.
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Of the patients who had microperimetry testing done, there 
was an overall increased retinal sensitivity across the board 
following microcurrent stimulation (Figures 8 and 9). Some 
patients, however, with large areas of geographic atrophy 
tended to increase their sensitivity in areas of their preferred 
retinal locus, where others with smaller to no areas of geo-
graphic atrophy increased their sensitivity in their fovea. There 
were no changes in retinal thickness measured by OCT.
?????????????
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?
????????? ???? ???? ??????????????????????????? ?????????????????????
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Figure 8 Pre- and post-microperimetry fields on three patients.
Notes: MP-1 fields of patient 16: (A) pretreatment, (B) following two treatments, and (C) after five treatments at 6 months.
Abbreviation: MP-1, microperimeter-1.
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Figure 9 Pre- and post-microperimtery fields on two patients.
Notes: MP-1 fields of patient 17: (A) pretreatment and (B) posttreatment after three treatments.
Abbreviation: MP-1, microperimeter-1.
Discussion
In this study, dual channel FSM therapy was used in a nonin-
vasive procedure, involving transcutaneous electrical current 
with very low intensity. Clinically, if further studies support 
positive trends over time, this would be a relatively easy treat-
ment modality for physicians to offer their patients, either 
as a weekly in-office treatment or a home-based therapy. 
Interested clinicians would benefit from a course, such as 
the one available at www.frequencyspecific.com.
Mechanisms of possible tissue effects that may explain 
some of the changes in visual function by FSM are theoreti-
cal. No direct measures of tissue changes were taken. Many 
of the following hypotheses are derived from animal models 
using TES:
•	 Effects on the mitochondrial Krebs cycle increase produc-
tion of intracellular adenosine triphosphate. Transmem-
brane transport through voltage-gated ion channels is 
dependent on adenosine triphosphate. Voltage-gated ion 
channels may be positively influenced by the presence of 
external current flow, enabling the configuration change 
that precedes ion flow.19
•	 Influence of extremely low-frequency electromagnetic 
fields has been demonstrated to have beneficial and 
therapeutic effects on voltage-gated calcium channels 
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via influence on the G-protein channel through the nitric 
oxide-cyclic GMP–protein kinase pathway.25
•	 Alteration in gene expression, such as upregulation of Bcl-2, 
ciliary neurotrophic factor, and brain-derived neurotrophic 
factor; downregulation of Bax; suppression or inhibition 
of inflammatory factors, such as IL-1β and TNF-α; and 
transcriptome changes in 490 genes have been identified, 
including neuroprotective genes, such as Bax or those that 
are part of the TNF family. Additionally, upregulation of 
intrinsic insulin-like growth factor-1 (Mueller cell activa-
tion and diffusion into the inner retina) was found.9,10
•	 Increase in choroidal vessel blood flow in normal human 
subjects, measured in ten healthy subjects following 
TES using a laser speckle flowgraphy, showed that there 
was statistically significant increase in blood flow in the 
macular zone, which may account for the improvements 
in patients with ischemia.26
Although, the majority of the patients demonstrated both 
subjective and objective improvements, follow-up is still 
relatively short and determination of long-term efficacy is 
as yet unproven. Further, the training effects of repeated VA 
measures are unknown and the VA testers were not blinded, 
adding the possibility of examiner bias. The magnitude of 
changes in VA in this patient population was similar to that 
seen by Shinoda et al3 and perhaps less than that reported by 
Anastassiou, although follow-up was extremely short in the 
latter study. It is unclear whether and to what degree early 
improvements were subsequently abrogated in this group of 
patients, since follow-up varied considerably from patient to 
patient. However, those patients who continued treatment 
once a month, for at least 6 months, maintained their VA 
gains. There was sufficient follow-up to enable mean changes 
over time to be determined, as in Figures 3 and 4, for at least 
the first 30 days. The substantial changes observed over this 
period, combined with continued improvement for patients 
who continued treatment once a month, are encouraging for 
future studies, which could be made double-blind by includ-
ing a control arm with sham treatment.
It is likely that patients would need to continue treatment 
for the duration of their lives, since the natural course of 
disease progression for age-related macular degeneration is 
a steady loss of vision. In the case of DAMD, there is a slow 
steady decline over what could be a long period (10 years or 
more), with the possibility of geographic atrophy occurring 
in a steady but more rapid decline with complete loss of 
central vision. In the case of WAMD, there is rapid precipi-
tous loss of vision over a very short (days to months) time 
if left untreated. This efficacy and safety study suggests that 
microcurrent stimulation can be safely administered to this 
population.
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